News
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: MediClin AG: Disclosure of Significant Transactions with Related Parties pursuant to Section 111c of the German Stock Corporation Act (AktG)
Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its fourth
Humana, Monogram Health Announce New Agreement that Enhances In-home Kidney Care in Four States
Kidney care provider Monogram Health and leading health and well-being company Humana Inc. (NYSE: HUM) have announced a new value-based care agreement for most Humana Medicare Advantage HMO and PPO
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
BIOCORP und NOVO NORDISK verstärken ihre Partnerschaft mit einer neuen Vereinbarung über den Mallya® Smart Sensor
BIOCORP (FR0012788065 - ALCOR / Eligible PEA-PME) (Paris:ALCOR), ein französisches Unternehmen, das auf das Design, die Entwicklung und die Herstellung innovativer medizinischer Geräte
BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices
MD Medical Group Investments Plc: Results of the Board of Directors meeting
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement
EQS-Adhoc: MEDICLIN reaches agreement regarding early renewal of lease agreements for 20 clinic locations and settlement of lease dispute with (former) shareholders
Humana expands Medicare Advantage health plan offerings into Rhode Island, Wyoming and 140 new counties nationwide in 2023
Leading health and well-being company Humana Inc. (NYSE: HUM) is offering Medicare Advantage plans for the first time in two new states and 140 new U.S. counties, expanding cost-effective health
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides
EQS-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2023 Second Quarter Conference Call to be Held on November 7, 2022
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting from
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter of 2022.
Press release date / time: Monday, November 7, shortly after 22:05
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc